<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml>
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="0" size="11" family="Times" color="#000000"/>
	<fontspec id="1" size="10" family="Times" color="#000000"/>
	<fontspec id="2" size="10" family="Times" color="#000000"/>
<text top="72" left="155" width="305" height="16" font="0"><b>ENCODE Antibody Validation Documentation </b></text>
<text top="89" left="101" width="414" height="16" font="0"><b>Transcription factor: Activating transcription factor 3 (GeneID </b></text>
<text top="105" left="292" width="32" height="16" font="0"><b>467) </b></text>
<text top="121" left="77" width="3" height="13" font="1"><b> </b></text>
<text top="134" left="77" width="344" height="13" font="1"><b>From:  Myers Lab, HudsonAlpha Institute for Biotechnology </b></text>
<text top="148" left="77" width="340" height="13" font="1"><b>Contact Person:</b> Dr. Florencia Pauli (fpauli@hudsonalpha.org) </text>
<text top="162" left="77" width="3" height="13" font="2"> </text>
<text top="176" left="77" width="3" height="13" font="2"> </text>
<text top="190" left="77" width="281" height="13" font="1"><b>Transcription factor:</b> ATF3 (GeneID 467; ~20 kDa) </text>
<text top="203" left="77" width="3" height="13" font="1"><b> </b></text>
<text top="217" left="77" width="322" height="13" font="1"><b>Antibody:</b> ATF3 (C-19), Santa Cruz Biotechnology (sc-188) </text>
<text top="231" left="77" width="398" height="13" font="2">Rabbit polyclonal, epitope mapping at C-terminus of ATF3 of human origin </text>
<text top="245" left="77" width="353" height="13" font="2">Web: http://www.scbt.com/datasheet-188-atf-3-c-19-antibody.html </text>
<text top="259" left="77" width="3" height="13" font="2"> </text>
<text top="272" left="77" width="3" height="13" font="2"> </text>
<text top="286" left="77" width="236" height="16" font="0"><b>Validation 1: Immunoblot Analysis  </b></text>
<text top="312" left="77" width="467" height="13" font="2">For an antibody to meet ENCODE validation standards, a single band of the predicted </text>
<text top="326" left="77" width="467" height="13" font="2">size,  or  a  band  of  no  less  than  half  the  total  signal,  must  be  detected  in  a  lane  on  a </text>
<text top="340" left="77" width="74" height="13" font="2">Western blot. </text>
<text top="364" left="77" width="3" height="13" font="2"> </text>
<text top="388" left="77" width="187" height="13" font="1"><b>a.  Vendor immunoblot analysis  </b></text>
<text top="548" left="215" width="3" height="13" font="2"> </text>
<text top="569" left="81" width="422" height="13" font="1"><b>Figure  Legend:</b>  Western  blot  analysis  of  ATF3  expression  in  RAW  264.7 </text>
<text top="583" left="81" width="94" height="13" font="2">whole cell lysate. </text>
<text top="607" left="81" width="3" height="13" font="2"> </text>
<text top="630" left="81" width="3" height="13" font="1"><b> </b></text>
<text top="654" left="81" width="3" height="13" font="1"><b> </b></text>
<text top="678" left="81" width="3" height="13" font="1"><b> </b></text>
<text top="702" left="81" width="3" height="13" font="1"><b> </b></text>
</page>
<page number="2" position="absolute" top="0" left="0" height="792" width="612">
<text top="72" left="81" width="203" height="13" font="1"><b>b.  Myers Lab immunoblot analysis</b> </text>
<text top="96" left="77" width="131" height="13" font="1"><b>Western blot protocol  </b></text>
<text top="120" left="77" width="467" height="13" font="2">Whole cell lysates were immunoprecipitated using primary antibody, and the IP fraction </text>
<text top="134" left="77" width="467" height="13" font="2">was  loaded  on  a  12%  acrylamide  gel  and  separated  with  a  Bio-Rad  PROTEAN  II  xi </text>
<text top="148" left="77" width="467" height="13" font="2">system.  After  separation,  the  samples  were  transferred  to  a  nitrocellulose  membrane </text>
<text top="161" left="77" width="467" height="13" font="2">with an Invitrogen iBlot system.  Blotting with primary (same as that used for IP) and </text>
<text top="175" left="77" width="467" height="13" font="2">secondary HRP-conjugated antibodies was performed on an Invitrogen BenchPro 4100 </text>
<text top="189" left="77" width="467" height="13" font="2">system.  Visualization  was  achieved  using  SuperSignal  West  Femto  solution  (Thermo </text>
<text top="203" left="77" width="62" height="13" font="2">Scientific).  </text>
<text top="227" left="77" width="10" height="13" font="2">   </text>
<text top="607" left="77" width="3" height="13" font="2"> </text>
<text top="607" left="511" width="3" height="13" font="2"> </text>
<text top="628" left="122" width="354" height="13" font="1"><b>Figure Legend:</b> ATF3 immunoblot: IP-western with sc-188 ATF3 </text>
<text top="642" left="122" width="354" height="13" font="2">antibody  in  nuclear  lysate  (NE)  or  whole  cell  lysates  (WCL)  of </text>
<text top="656" left="122" width="354" height="13" font="2">GM12878, K562, and HeLa. Heavy chain of IgG is indicated, and </text>
<text top="669" left="122" width="191" height="13" font="2">ATF3 band is indicated at ~23 kDa. </text>
<text top="693" left="77" width="3" height="13" font="2"> </text>
</page>
<page number="3" position="absolute" top="0" left="0" height="792" width="612">
<text top="72" left="77" width="3" height="13" font="2"> </text>
<text top="96" left="77" width="167" height="16" font="0"><b>Validation 2: In progress </b></text>
</page>
</pdf2xml>
